High-Affinity Talks: Computational/AI methods in biologics discovery

​Our next High-Affinity Talks features Konrad Krawczyk, Founder of NaturalAntibody.

​Computational methods, of which AI/ML is a sizeable subset currently, have held the promise to revolutionize drug discovery for close to half a century now. Computional methods are regularly used in drug discovery workflows as a supporting role, rather than process-driving capacity, where heavy lifting is still carried by the wetlab. Data, or rather its scarcity, is often posited as the culprit here.

​Backed by experience in collecting and harmonizing biologics data from the public domain, we will address the data scarcity problem, showing that it is only part of the issue, with the good news that it is solvable (but with no obvious shortcuts).

​Hosted by MiLaboratories, we will cover case studies of where computational/modeling methods offer value in biologics discovery, how to select the right tool for the right task and where to identify computational failure early on.